Urgent.News

What's breaking now, across thousands of outlets.

Business

Takeover target: Is the German biotech industry facing a sell-off?

After Tubulis, biotech hopeful ITM is also going to a foreign pharmaceutical company. Whether such sales mean a sell-off is controversial. The industry continues to lack one thing above all else.

Translated from German Read in German

Takeover target: Is the German biotech industry facing a sell-off?

German biotech companies are attracting takeover bids, with recent examples including ITM, acquired by Australia's Telix for over $1.65 billion, and Tubulis, bought by US pharma giant Gilead for over $3 billion. The deals have raised concerns that German firms are developing new therapies while foreign companies reap the benefits.

The German biotech industry's financing volume was €864 million until September, 23% down from the previous year, according to the industry association Bio Deutschland. Experts warn that without more growth capital and a functioning stock market access, German biotech companies may be forced to seek large foreign partners.

Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.

Read the original at handelsblatt.com →

More in Business

More from Monday 5 October →